biodegradable nanomedicines
toxic multimodal nanomedicines
large scale GMP nanomedicines
Large scale GMP production of nanomedicines
cancer patients
ovarian cancer
multimodal immunotherapy Phase
multimodal precision cancer immunotherapy PRECIOUS aims
new cancer medicines
tumour microenvironment
types of GMP biodegradable nanoparticles
tumour antigens
anti-tumour immunity
Scaling
vigorous immune responses
immune activators
Clinical Phase
local injection of nanoparticles
toxicity
local delivery of vaccines
trials
compounds
Objective
reverse suppression
bottlenecks
leading  industrial partners
industrial leadership
clinical studies
new immunotherapies
renowned academic partners
time reverse immunosuppression
nanotechnology
translation
advanced manufacturing KET technologies
excellent immunomodulator track record
year
lymphnodes
European health care system
nanovaccine
major impact
dose
marketing development
lower costs
efficacy
Relevance
platform
prostate
Vaccination
hurdle